156 results
Page 6 of 8
8-K
EX-99.1
2d1rsqcfxs
6 Mar 14
TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2013 Financial Results and Business Update
12:00am
8-K
EX-99.1
xa8hvt5jr97
11 Dec 13
TG Therapeutics, Inc. Announces Presentation of Encouraging Clinical Activity of TGR-1202 in an Ongoing Multi-center Phase I Clinical Study
12:00am
8-K
EX-99.1
c6pccu9m0b
29 Oct 13
Other Events
12:00am
424B5
yz10ovgy
18 Jul 13
Prospectus supplement for primary offering
12:00am
424B5
paw2qk0eo54djj9vcvlx
17 Jul 13
Prospectus supplement for primary offering
12:00am
424B5
u4p14xdq7xayantk3o
21 Jun 13
Prospectus supplement for primary offering
12:00am
8-K
EX-99.1
2socee
3 Jun 13
40% of Rituximab-Refractory Patients (2/5) Achieve a Complete Response
12:00am
8-K
EX-99.1
gic9zx
12 Mar 13
TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2012 Financial Results and Business Update
12:00am
8-K
EX-99.1
ya7n3pk
10 Dec 12
Dr. Owen O’Connor Presents Early Clinical Data on the Safety and Efficacy from two Ongoing Phase I Trials of TG-1101
12:00am
8-K
EX-99.1
mlzxn875ievtl
8 Nov 12
TG Therapeutics, Inc. Announces Third Quarter 2012 Financial Results and Business Update
12:00am
8-K
EX-99.1
wydqwo hm
21 Aug 12
IND Filing Expected Fourth Quarter 2012
12:00am